India’s capital markets are sophisticated at pricing high-ROE, low-capex, cash-generative generics franchises with predictable trailing earnings. That same logic applied to a company stepping up R&D and taking on debt to fund a platform bet, appears a risk rather than optionality, producing a valuation discount precisely when conviction should command a premium.
Zydus Lifesciences, trading at a meaningful discount to peers despite genuine innovation-led capital deployment, and Wockhardt, dismissed as a struggling generics company for two decades while building what is now a landmark FDA-approved discovery pipeline, are two live, verifiable illustrations of the same underlying mispricing.
This mispricing is a real constraint on the capital allocation we have been talking about and is a real opportunity for whoever is positioned to look past it.
“My Pharma Reviews - The Podcast” is now available for you to listen on your favourite podcasting apps like Spotify and Apple.
